BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu Q, Wang Y, Huang W. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma. Int Immunopharmacol 2021;92:107333. [PMID: 33486322 DOI: 10.1016/j.intimp.2020.107333] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Ping S, Gong R, Lei K, Qing G, Zhang G, Chen J. Development and validation of a ferroptosis-related lncRNAs signature to predict prognosis and microenvironment for melanoma. Discov Onc 2022;13:125. [DOI: 10.1007/s12672-022-00581-3] [Reference Citation Analysis]
2 Zhong Z, Xu M, Tan J. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma. Pathol Oncol Res 2022;28:1610670. [DOI: 10.3389/pore.2022.1610670] [Reference Citation Analysis]
3 Chen M, Wu G, Hua S, Zhao Z, Li H, Luo M. Identification and validation of a prognostic model of necroptosis-related lncRNAs in hepatocellular carcinoma. Front Genet 2022;13:907859. [DOI: 10.3389/fgene.2022.907859] [Reference Citation Analysis]
4 Wang Y, Ji Y, Xu Q, Huang W. Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma. Front Genet 2022;13:866340. [DOI: 10.3389/fgene.2022.866340] [Reference Citation Analysis]
5 Pallozzi M, Di Tommaso N, Maccauro V, Santopaolo F, Gasbarrini A, Ponziani FR, Pompili M. Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Cancers 2022;14:4631. [DOI: 10.3390/cancers14194631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang HQ, Qian CH, Guo ZY, Li PM, Qiu ZJ. Long noncoding RNA negative regulator of antiviral response contributes to pancreatic ductal adenocarcinoma progression via targeting miR-299-3p. World J Gastroenterol 2022; 28(35): 5141-5153 [DOI: 10.3748/wjg.v28.i35.5141] [Reference Citation Analysis]
7 Yu J, Sun X, Zhao Y, Zheng C, Zhou B. Development and Validation of an Individualized Immune Prognostic Signature in HNSCC.. [DOI: 10.21203/rs.3.rs-2007096/v1] [Reference Citation Analysis]
8 Hu C, Cai D, Zhong M, Fan D, Li C, Lv M, Huang Z, Wang W, Wu X, Gao F. Predicting prognosis and immunotherapy response among colorectal cancer patients based on a tumor immune microenvironment-related lncRNA signature. Front Genet 2022;13:993714. [DOI: 10.3389/fgene.2022.993714] [Reference Citation Analysis]
9 Liu CZ, Li JD, Chen G, He RQ, Lin R, Huang ZG, Li JJ, Du XF, Lv XP. A cohesin-associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma. FEBS Open Bio 2022;12:1857-74. [PMID: 36052535 DOI: 10.1002/2211-5463.13474] [Reference Citation Analysis]
10 Xu Y, Liu R. Analysis of the role of m6A and lncRNAs in prognosis and immunotherapy of hepatocellular carcinoma. Heliyon 2022;8:e10612. [PMID: 36158075 DOI: 10.1016/j.heliyon.2022.e10612] [Reference Citation Analysis]
11 Lin XH, Zhang DY, Liu ZY, Tang WQ, Chen RX, Li DP, Weng S, Dong L. lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation. J Transl Med 2022;20:379. [PMID: 36038907 DOI: 10.1186/s12967-022-03573-7] [Reference Citation Analysis]
12 Song B, Tian L, Zhang F, Lin Z, Gong B, Liu T, Teng W. A novel signature to predict thyroid cancer prognosis and immune landscape using immune-related LncRNA pairs. BMC Med Genomics 2022;15:183. [PMID: 35996170 DOI: 10.1186/s12920-022-01332-7] [Reference Citation Analysis]
13 Chen B, Yang Z, Lang Z, Tao Q, Zhang R, Zhan Y, Xu X, Zhu K, Zheng J, Yu Z, Yu S. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. BMC Cancer 2022;22:867. [PMID: 35941582 DOI: 10.1186/s12885-022-09925-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cao J, Xu Y, Liu X, Cai Y, Luo B. Innovative signature establishment using lymphangiogenesis-related lncRNA pairs to predict prognosis of hepatocellular carcinoma. Heliyon 2022;8:e10215. [PMID: 36033263 DOI: 10.1016/j.heliyon.2022.e10215] [Reference Citation Analysis]
15 Wang D, Zhang L, Zhang Y, Zhang Y, Xu S. A ferroptosis-associated lncRNAs signature predicts the prognosis of hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e29546. [PMID: 35839000 DOI: 10.1097/MD.0000000000029546] [Reference Citation Analysis]
16 Yang Y, Shi L, Zhang J, Zheng Y, Wu G, Sun J, Liu M, Chen Z, Wang Y, Ji R, Guo Q, Zhou Y. A Novel Matrisomal-Related LncRNA Signature Associated With Survival Outcome and Immune Evasion in Patients With Gastric Cancer. Front Oncol 2022;12:926404. [DOI: 10.3389/fonc.2022.926404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang J, Ling S, Ni J, Wan Y. Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma. BMC Cancer 2022;22:638. [PMID: 35681134 DOI: 10.1186/s12885-022-09662-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rizzo A, Ricci AD. Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon? Expert Review of Precision Medicine and Drug Development 2022;7:50-7. [DOI: 10.1080/23808993.2022.2075724] [Reference Citation Analysis]
19 Wang Q, Tang Y, Ge Y, Zhang S, Zheng M. Long non-coding RNA NRAV enhances proliferation and invasion of hepatocellular carcinoma cells by modulating the Wnt/β-catenin signaling pathway. Bioengineered 2022;13:10026-37. [PMID: 35436415 DOI: 10.1080/21655979.2022.2062977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Rizzo A, Cusmai A, Gadaleta-Caldarola G, Palmiotti G. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma? Expert Rev Gastroenterol Hepatol 2022;16:333-9. [PMID: 35403533 DOI: 10.1080/17474124.2022.2064273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Wu L, Yin X, Jiang K, Yin J, Yu H, Yang L, Ma C, Yan S. Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma. Cancer Med 2022. [PMID: 35142083 DOI: 10.1002/cam4.4552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Zhu XL, Li Q, Shen J, Shan L, Zuo ED, Cheng X. Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database. Transl Cancer Res 2021;10:5337-51. [PMID: 35116381 DOI: 10.21037/tcr-21-2440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Huang B, Liu J, Lu J, Gao W, Zhou L, Tian F, Wang Y, Luo M, Liu D, Xie C, Xun Z, Liu C, Wang Y, Ma H, Guo J. Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer. Front Oncol 2021;11:812785. [PMID: 35047414 DOI: 10.3389/fonc.2021.812785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Huang S, Zhang J, Lai X, Zhuang L, Wu J. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. Front Mol Biosci 2021;8:781307. [PMID: 35004851 DOI: 10.3389/fmolb.2021.781307] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
25 Rizzo A, Ricci AD, Di Federico A, Frega G, Palloni A, Tavolari S, Brandi G. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand? Front Oncol 2021;11:803133. [PMID: 34976841 DOI: 10.3389/fonc.2021.803133] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
26 Liu JL, Liu YS, Zheng MJ, He HY. The management of bone defect using long non-coding RNA as a potential biomarker for regulating the osteogenic differentiation process. Mol Biol Rep 2022;49:2443-53. [PMID: 34973122 DOI: 10.1007/s11033-021-07013-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wang Y, Ge F, Sharma A, Rudan O, Setiawan MF, Gonzalez-Carmona MA, Kornek MT, Strassburg CP, Schmid M, Schmidt-Wolf IGH. Immunoautophagy-Related Long Noncoding RNA (IAR-lncRNA) Signature Predicts Survival in Hepatocellular Carcinoma. Biology (Basel) 2021;10:1301. [PMID: 34943216 DOI: 10.3390/biology10121301] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
28 Ye D, Liu Y, Li G, Sun B, Peng J, Xu Q. A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. Front Oncol 2021;11:766072. [PMID: 34868990 DOI: 10.3389/fonc.2021.766072] [Reference Citation Analysis]
29 Zhu R, Li X, Cai Z, Liang S, Yuan Y, Xu Y, Lai D, Zhao H, Yang W, Bian J, Liu L, Xu G. Risk Scores Based on Six Survival-Related RNAs in a Competing Endogenous Network Composed of Differentially Expressed RNAs Between Clear Cell Renal Cell Carcinoma Patients Carrying Wild-Type or Mutant Von Hippel-Lindau Serve Well to Predict Malignancy and Prognosis. Front Oncol 2021;11:726671. [PMID: 34760693 DOI: 10.3389/fonc.2021.726671] [Reference Citation Analysis]
30 Zhou C, Zhang H, Lu L. Identification and Validation of Hypoxia-Related lncRNA Signature as a Prognostic Model for Hepatocellular Carcinoma. Front Genet 2021;12:744113. [PMID: 34650600 DOI: 10.3389/fgene.2021.744113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Lin Z, Pang K, Li H, Zhang X, Wan J, Zheng T, Liu T, Peng W. Characterization of Immune-Related Long Non-coding RNAs to Construct a Novel Signature and Predict the Prognosis and Immune Landscape of Soft Tissue Sarcoma. Front Cell Dev Biol 2021;9:709241. [PMID: 34631703 DOI: 10.3389/fcell.2021.709241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Xu Q, Chen S, Hu Y, Huang W. Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. Front Genet 2021;12:739975. [PMID: 34589117 DOI: 10.3389/fgene.2021.739975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chen ZA, Tian H, Yao DM, Zhang Y, Feng ZJ, Yang CJ. Identification of a Ferroptosis-Related Signature Model Including mRNAs and lncRNAs for Predicting Prognosis and Immune Activity in Hepatocellular Carcinoma. Front Oncol 2021;11:738477. [PMID: 34568075 DOI: 10.3389/fonc.2021.738477] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
34 He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol 2021;11:716844. [PMID: 34552872 DOI: 10.3389/fonc.2021.716844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
36 Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs 2021;:1-9. [PMID: 34429006 DOI: 10.1080/13543784.2021.1972969] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 27.0] [Reference Citation Analysis]
37 Xu Q, Xu H, Deng R, Li N, Mu R, Qi Z, Shen Y, Wang Z, Wen J, Zhao J, Weng D, Huang W. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy. Front Cell Dev Biol 2021;9:669145. [PMID: 34422799 DOI: 10.3389/fcell.2021.669145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Xu Q, Xu H, Chen S, Huang W. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:710207. [PMID: 34409040 DOI: 10.3389/fcell.2021.710207] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
39 Xu Q, Xu H, Deng R, Wang Z, Li N, Qi Z, Zhao J, Huang W. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. Cancer Cell Int 2021;21:342. [PMID: 34217320 DOI: 10.1186/s12935-021-02049-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]